Gefitinib vs tri‐weekly paclitaxel plus carboplatin
Overall survival · EGFR M+ patients with NSCLC
Gefitinib showed no clear difference in overall survival compared with paclitaxel + carboplatin (high certainty).
1 finding from 1 review
- First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes onlyHR 0.95 [0.77, 1.18]2 studies · 489 participantsHigh